BET-BD1 Selective Neuroimaging probes for Alzheimer's disease research

用于阿尔茨海默病研究的 BET-BD1 选择性神经影像探针

• 批准号: 10628245
• 负责人: Changning Wang
• 金额: $ 244.23万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-05-01 至 2026-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10628245
• 关键词: Academia; Acceleration; Accounting; Aging; Alzheimer' s Disease; Animals; BRD2 gene; Binding; Biological Assay; Brain; Bromodomain; Bromodomains and extra-terminal domain inhibitor; C-terminal; Carbon; Cellular biology; Chemicals; Clinical Trials; Coin; Complex; DNA Sequence; Data; Dementia; Development; Disease; Disease Progression; Dose; Drug Kinetics; Drug Targeting; Enzymes; Epigenetic Process; Evaluation; FDA approved; Fluorine; Functional disorder; General Hospitals; Genetic Transcription; Genome; Goals; Grant; Growth; Histone Acetylation; Human; Image; Imaging Techniques; Industry; Label; Lead; Learning; Massachusetts; Measurement; Memory; Metabolism; Methods; Modification; Mus; N-terminal; Nature; Neurodegenerative Disorders; Neurology; Oncology; Patient Selection; Persons; Pharmaceutical Preparations; Pharmacotherapy; Plasma; Play; Positron-Emission Tomography; Preventive measure; Process; Property; Protein Family; Radio; Radiolabeled; Reader; Reporting; Research; Resources; Rodent; Role; Safety; Scientist; Series; Structure; Techniques; Tertiary Protein Structure; Testing; Therapeutic Trials; Tissues; Tracer; Translating; Validation; analog; biomedical imaging; clinical application; design; effective therapy; epigenetic regulation; human disease; human imaging; imaging facilities; imaging probe; imaging study; in vivo; in vivo imaging; kinetic model; member; molecular imaging; neuroimaging; non-invasive imaging; nonhuman primate; novel; novel therapeutic intervention; novel therapeutics; pharmacologic; prevent; protein function; radiochemical; radiotracer; response; scaffold; serial imaging; small molecule therapeutics; therapeutic target; tool; tool development; uptake

Project Summary Epigenetics refers to functional modifications to the genome that do not involve a change in the DNA sequence. Growing evidence have shown that modulation of epigenetic processes may be a new therapeutic approach applicable across most human diseases. The epigenetic “readers” have been implicated in multiple functions and associated with various human diseases, such as Alzheimer’s disease (AD). The bromodomain and extra- terminal domain (BET) family of proteins contain tandem bromodomains which bind to acetylated histones. Four BET members (BRD2, BRD3, BRD4 and BRDT) are found in humans, contain two bromodomains each (N- terminal bromodomain (BD1) or C-terminal bromodomain (BD2)). Recently, BET inhibitors have been reported to have a key impact on brain function, including learning and memory. Our overall goal is to develop PET radiotracers target BET-BD1 in the brain for comparison to disease states and for assessing in vivo BET-BD1 target engagement with BET drug treatment. Moreover, these techniques will accelerate the discovery of small molecule therapeutics that selectively interacts with the specific BET-BD1 domain. Currently, there are no PET tracers available for imaging BET-BD1 in the brain, although several BET inhibitors or selective BET-BD1 inhibitors have been reported or radiolabeled. The project is designed to perform IND-enabling studies for a novel PET imaging probe for BD1 domain of BET.

项目概要 表观遗传学是指不涉及 DNA 序列变化的基因组功能修饰。 越来越多的证据表明表观遗传过程的调节可能是一种新的治疗方法 适用于大多数人类疾病。表观遗传“读者”具有多种功能。 并与多种人类疾病有关，例如阿尔茨海默病（AD）。 末端结构域 (BET) 蛋白质家族包含与乙酰化组蛋白结合的串联溴结构域。 BET 成员（BRD2、BRD3、BRD4 和 BRDT）存在于人类中，每个成员包含两个溴结构域（N- 最近报道了 BET 抑制剂。 对大脑功能（包括学习和记忆）产生关键影响 我们的总体目标是开发 PET。 放射性示踪剂以大脑中的 BET-BD1 为目标，用于与疾病状态进行比较并评估体内 BET-BD1 此外，这些技术将加速小分子药物治疗的发现。 选择性与特定BET-BD1结构域相互作用的分子疗法目前还没有PET。 尽管有几种 BET 抑制剂或选择性 BET-BD1，但示踪剂可用于大脑中 BET-BD1 的成像 该项目旨在针对 IND 进行研究。 针对 BET BD1 结构域的新型 PET 成像探针。